Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
SAN FRANCISCO, Aug. 29, 2017 -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming Morgan Stanley 15th Annual Global Healthcare Conference in New York, NY.
iRhythm’s management is scheduled to present on Tuesday, September 12, 2017 at 12:55pm ET. Interested parties may access a webcast of the presentation on the “Investors” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.
Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 [email protected] Media Contact Aaron Murphy (415) 229-3331 [email protected]
